Icon
+91 94997 68112
Login Register

AZILECT (nda021641)- (EQ 0.5MG BASE,EQ 1MG BASE)

RASAGILINE MESYLATE TEVA
EQ 0.5MG BASE,EQ 1MG BASE
Yes No
2027-Aug-27 2011-May-16
None None
None No
AZILECT, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease
7 1 6
Total Other Developers 10
Drugs with Suitability No
EQ 0.5MG BASE ** ** Up - 4
EQ 1MG BASE ** ** Up - 4
NDA Sales Available Total Generic Sales Available
Yes 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** **** *** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** **** **.** (****) *** ** (****), ****** ********** ****, ***************, *************, ***********, ***** **** ******, ***** (***) ***
****** ****** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****,, ***, *** ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** **** **. *-*** ** *-*** & **, ***** *** & ***** **, ***** ********** ******, *****, *** ******, ***** (***) ***

Download GenUS Drug Report

Download GenUS Detailed Report

To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.